News

The approval of the company’s supplemental Biologics License Application makes it the first and only systemic therapy to treat pediatric patients aged 4 to 17 affected by the

In connection with the acquisition, EnBiotix has established EnBiotix. EnBiotix has also initiated a collaboration with Leipzig University and AMPT’s scientific co-founder, Professor Ralf Hoffmann, Ph.D. EnBiotix chairman

BCT-197 is currently in a Phase 2 study for the treatment of acute exacerbations of COPD (AECOPD). This study evaluated potential drug interactions between acumapimod and the antibiotic

The insulin glargine, which has been co-developed by Mylan and Biocon, is used to treat adults with Type 2 diabetes and adults and paediatric patients with type 1

Again, we are looking to further cement our foothold in the substantial pharmaceutical drug development industry, we expect our IGXBio, GenePro drug development program to be a major pharmaceutical

Researchers from the Massachusetts Institute of Technology (MIT), the University of Brasilia and the University of British Columbia have engineered an antimicrobial peptide that they claim will destroy

The biotechnology company will use the proceeds from financing to accelerate and expand pipeline of oncolytic viral immunotherapies. Turnstone CEO Sammy Farah said: “We are taking a rapid and expansive

Pursuant to its recent End of Phase II meeting with the U.S. Food & Drug Administration (FDA) Division of Pulmonary, Allergy and Rheumatology Products, Aurinia believes this Phase

The acquisition includes remetinostat, a skin-directed HDAC inhibitor, and birinapant, a bivalent SMAC mimetic, and all intellectual property and data associated with Tetralogic’s HDAC inhibitor and SMAC mimetic